A Phase 1/2 Study of REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer

Targeted Disease(s):
Lung Cancer

Purpose of Study:

The primary objective of the dose escalation (phase 1) part of the study is to assess the safety, tolerability, and pharmacokinetics (PK) of REGN5093 for determination of the maximum tolerated dose (MTD) and/or definition of the recommended phase 2 dose (RP2D) of REGN5093 in patients with MET-altered Non-small cell lung cancer(NSCLC).The primary objective of the dose expansion (phase 2) part of the study is to assess preliminary anti-tumor activity of REGN5093 as measured by the objective response rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST 1.1)

Study Dates:
January 17, 2020 - February 15, 2024

Study Design:
Controlled Design

Study Location:

Lead Institution:
Regeneron Pharmacuticals


Regeneron Pharmaceuticals


Name: Massive Bio
Phone: 844-627-7246
Email: [email protected]

ClinicalTrails.gov Identifier:

Register for Trial
Asthma Basics Workshop
, | Jul 21, 2023
Newly Diagnosed With an Interstitial Lung Disease
, | Jul 25, 2023